Table 3 Clinical outcomes of the overall population receiving benralizumab treatment at 1-year of follow-up

Severe exacerbations, mean (SD)

2.5 (2.3)

0.36 (0.98)

Patients with zero severe exacerbations, n/N (%)

31/204 (15.2%)

166/204 (81.4%)

Changes in severe exacerbations

N = 173

Patients with reduction in exacerbations, n/N (%)

161/173 (93.1%)

Patients achieving ≥ 50% reduction in severe exacerbations, n/N (%)

159/173 (91.9%)

Percentage reduction in severe exacerbations

85.6%^a

Asthma-related healthcare resource use

N = 204

 N = 204

Patients with no hospitalizations, n/N (%)

159/203 (78.3%)

196/204 (96.1%)

Hospitalizations, mean (SD)

0.4 (0.9)

0.1 (0.3)

Patients with no ED visits, n/N (%)

118/204 (57.8%)

188/204 (92.2%)

ED visits, mean (SD)

0.9 (1.8)

0.1 (0.4)

Changes in use of asthma-related healthcare resources

N = 204

Percentage reduction in mean hospitalizations

75%

Percentage reduction in ED visits

88.9%^a

Lung function

N = 170

 N = 134

Pre-BD FEV₁ (mL), mean (SD)

1909 (780)^b

2186 (809)^c

Pre-BD FEV₁ (% predicted), mean (SD)

67.3 (21.0)

78.7 (22.2)

Patients with pre-BD FEV₁ ≥ 80%, n/N (%)

50/170 (29.4%)

62/134 (46.3%)

Changes in lung function

N = 114

Pre-BD FEV₁ increment ≥ 100mL, n/N (%)

76/114 (66.7)

Increase in pre-BD FEV₁ (mL), mean (SD)

331 (413)

Asthma control

N = 148

 N = 130

ACT score, mean (SD)

14.1 (5.1)

20.9 (4.8)

Patients with ACT score ≥ 20, n/N (%)

24/148 (16.2%)

96/130 (73.8%)

Patients with ACT score increase ≥ 3, n/N (%)

75/104 (72.1%)

Increase in ACT score, mean (SD)

6.6 (6.0)^d